ArticlePreventive medicine2026
Human behavioral pharmacology of cannabis: Insights on cannabis use disorder.
Article in Preventive medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveCannabis policy, public perception, and consumption patterns have undergone enormous shifts, yet the scientific understanding of these changes has lagged. Our objective is to describe how human behavioral pharmacology studies provide a rigorous framework for modelling Cannabis Use Disorder (CUD) and for informing the development of treatment approaches.
methodsThis narrative review synthesizes insights from over 25 years of human laboratory research, highlighting how behavioral pharmacology, e.g., dose, placebo control, behavioral specificity, inform the development of evidence-based therapies and targeting the behavioral drivers of CUD.
resultsKey takeaways: (1) Cannabis potency is not Δ
conclusionsRigorous, placebo-controlled human laboratory studies of the behavioral effects of cannabis are essential to informing a quickly evolving field complicated by the complexity of cannabis as a plant with a myriad of active constituents, regulatory hurdles, and industry narrative.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.